Tomi Environmental Solutions, Inc. (TOMZ) Q3 2026 earnings review
Tomi cancels its dilutive merger and earns an operating profit
Tomi Environmental Solutions, the maker of SteraMist disinfection systems, earned an operating profit while cancelling a dilutive merger. Revenue rose 24% from a year ago to $2.49 million as US equipment demand jumped, and lower overhead allowed chief executive Dr. Halden Shane to report $30,000 in operating income. The company also swapped $2.5 million of debt into stock and grew its order backlog to $2.8 million after the quarter closed.
| Revenue | $2.49M +24% from a year ago |
|---|---|
| Operating income | $30K -$321K a year ago |
| Quarter-end sales backlog | $2.5M $2.2M last quarter (rose to $2.8M after Q3) |
| Expected Q3 shareholders' equity | $3M–$4M $1.43M at June 30 by our math |
⚖️ Verdict: 🟢 Bullish
The story got better because calling off the Carbonium Core merger saved existing owners from giving up 90% of the company, while the core disinfection business proved it can break even on its own. One caution: the preliminary release held back bottom-line net loss and cash numbers pending an auditor review of the debt swap, and management quietly dropped any mention of its old $12 million full-year revenue target.
The question now is whether rising equipment orders are turning into actual cash collections and repeat chemical fluid refills. Either the $2.8 million backlog converts into cash-paying sales and steady refills, or unpaid customer bills force the company to sell more shares to fund operations. The full third-quarter filing with cash flow and receivable numbers will tell.
🐂 Bull Case
Carbonium Merger Cancelled Without a Penalty
In June, Tomi signed an agreement to merge with Carbonium Core, a nuclear-graphite startup. That deal required a $10 million financing and would have handed Carbonium's owners at least 90% of the combined business, leaving existing shareholders with a tiny slice of the SteraMist disinfection business.
On September 21, the disinfection group announced the "mutual termination of its definitive merger agreement with Carbonium Core, Inc." Each side paid its own legal bills, and Tomi owed no breakup fee. Days later, the US firm announced new design concepts for putting SteraMist into self-driving vehicles, drones and robots.
Cancelling the deal removes the biggest threat to existing shareholders because they keep 100% of the growing disinfection business. However, calling off the merger also means the $10 million cash injection tied to the deal will not happen.
What to watch: legal and professional fees in the third-quarter filing. Without merger work, overhead costs should drop in the fourth quarter.
Equipment Sales and Cost Cuts Brought Profit
Chief executive Dr. Halden Shane said Tomi "returned to positive operating income for the first time since the third quarter of 2024". The company earned $30,047 from operations, compared with a loss of $321,415 a year earlier and a loss of $244,142 last quarter.
Stronger US equipment demand and lower overhead drove the turnaround. Revenue rose 24% from a year ago to $2.49 million as US sales jumped 50% to $1.92 million. At the same time, operating expenses — sales, research and administrative overhead — fell 7% to $1.44 million, dropping by 19.5 percentage points of revenue to 57.8%.
Those overhead savings more than offset a 2.3 percentage point dip in gross margin to 59.0%, where cost of making the products rose to 41.0% of sales.
What to watch: fourth-quarter operating income. Staying profitable will show that normal equipment demand can cover overhead without further cost cuts.
Note Conversions Cut Debt and Lifted Equity
Tomi entered the third quarter with $2.95 million in total debt and needed higher stockholders' equity to keep its Nasdaq stock market listing. Management also carried out a 1-for-3 reverse stock split in July to lift the per-share price above Nasdaq's minimum rule.
Shane said the group "materially improved our capital structure during the quarter" as noteholders converted $2.5 million of debt into stock. By our math, that swap wiped out 85% of the debt on the June balance sheet. Tomi now expects September 30 shareholders' equity between $3 million and $4 million, up from $1.43 million in June by our math.
Removing that debt lowers future cash interest payments and helps satisfy Nasdaq's listing rules, though issuing those shares diluted existing owners.
What to watch: the total share count and remaining debt in the upcoming quarterly filing. Those numbers will show the exact dilution from the debt swap.
Order Backlog and Regulatory Approvals Keep Expanding
Customer orders and regulatory permits both moved higher this quarter, even as the company still waits for US medical-device and food-contact clearances. Sales backlog — booked orders waiting to be shipped — rose to $2.5 million at the end of September, up from $2.2 million in June and $0.9 million a year ago.
- Implied new orders booked in Q3: $2.79 million by our math, outpacing $2.49 million in shipped sales
- Post-quarter sales backlog: rose further to about $2.8 million
- SteraMist iHP enclosure orders: $2.3 million year-to-date, topping the prior four years combined ($1.6 million)
- New regulatory wins: US AgriMist approval for agriculture and cannabis, plus Ireland approval bringing Europe to 11 countries
After the quarter closed, a distributor in India also signed a pharmaceutical customer for a built-in enclosure, showing that custom rooms are driving the order book.
What to watch: fourth-quarter revenue conversion from the $2.8 million backlog. Turning those custom enclosure orders into shipped sales before year-end is the key test for fourth-quarter growth.
🐻 Bear Case
Missing $12 Million Target Needs a Huge Fourth Quarter
For the past two quarters, management told investors it expected at least $12 million in full-year 2026 revenue, pointing to a $35 million sales pipeline. In this third-quarter release, the company repeated the $35 million pipeline figure — with 25% in advanced stages — but did not mention the $12 million annual revenue target.
Nine-month revenue reached $6.39 million. By our math, hitting $12 million for the full year requires $5.61 million in fourth-quarter sales, which would be more than double this quarter's $2.49 million and a 451% jump from last year's fourth quarter ($1.02 million by our math).
Because the current order backlog sits at $2.8 million, Tomi would have to ship its entire backlog and book and ship another $2.8 million inside a single quarter. The $35 million pipeline is not turning into booked orders fast enough to support the old annual target.
What to watch: whether management repeats or drops the $12 million target in the quarterly filing. Dropping it would confirm that custom project deliveries are taking longer than planned.
Service Growth Stalled and Foreign Sales Dropped
Tomi pitches a razor-and-blade model where selling SteraMist machines and handheld applicators leads to steady, high-margin sales of BIT Solution — its hydrogen peroxide disinfectant fluid — and support services. While both sides of that model have grown this year, the quarterly mix remains lumpy and relies heavily on hardware shipments.
In the third quarter, service revenue grew 1.5% from a year ago to $415,000, down from 17% service share in the second quarter to 16.6% by our math. International sales dropped 22% to $572,000 despite new European permits, and the release gave no quarterly dollar figures for BIT Solution fluid or standalone applicators.
Moreover, gross margin fell 2.3 percentage points from a year ago to 59.0%. Because disinfectant fluid carries an 80% gross margin, a falling overall margin shows lower-margin equipment still dominates the mix.
What to watch: third-quarter BIT Solution fluid and applicator dollar sales in the quarterly filing. Slower fluid growth would mean new equipment customers are not yet ordering large repeat refills.
Risks this quarter didn't answer
Tomi published preliminary, unaudited numbers because "The Company and its independent registered public accounting firm have not yet completed their review of the accounting treatment for the Company’s convertible notes". Although the board named Niroshan Srirathan as permanent finance chief on October 11, leaving out the balance sheet and cash flow statement left four standing concerns unanswered.
- Bottom-line profit or loss: net loss and loss per share were held back pending the auditor's review of non-cash gains or losses on the $2.5 million debt swap.
- Cash balance and going-concern warning: cash sat at $322,000 in June, and this release gave no September cash figure or Equity Line of Credit share sales.
- Cash burn and unpaid customer bills: first-half operating cash flow was negative $1.3 million as accounts receivable rose, and Q3 collection figures are not yet available.
- Customer concentration: two buyers accounted for 33% of second-quarter sales, and the preliminary release did not disclose third-quarter concentration.
💲 Other KPIs
Product sales — disinfection machines, built-in enclosures and chemical fluid — rose 29.6% from a year ago and 11.8% from last quarter to $2.08 million. Growth slowed from last quarter's 184.5% jump, which compared against a weak period a year earlier, but product shipments still provided nearly all of the company's dollar growth.
Sales over the first nine months of 2026 rose 38.4% from a year ago to $6.39 million, already beating full-year 2025 revenue of $5.64 million. Year-to-date gross profit climbed 29% while operating expenses fell 11%, cutting the nine-month operating loss by 62%.
🔮 Guidance
New. Tomi expects shareholders' equity — total assets minus total liabilities — to land between $3 million and $4 million on September 30, once auditors finish reviewing the $2.5 million debt-to-equity swap. By our math, the $3.5 million middle of the range is up $2.07 million from $1.43 million in June, driven by turning convertible notes into common shares.
❓ Key Questions
Is the $12 million full-year revenue target still active?
Management reaffirmed its target of at least $12 million in 2026 revenue back in July, but left the number out of this release. Hitting $12 million requires $5.61 million in fourth-quarter sales on a $2.8 million backlog.
How much cash did Tomi hold on September 30?
The company held $322,000 in cash in June after burning $1.3 million in operations during the first half, and calling off the Carbonium merger removed a planned $10 million financing.
Did customers pay down the $1.89 million June receivables balance?
Net unpaid customer bills jumped by $1.13 million in the second quarter, driving the first-half cash outflow. Investors need the third-quarter cash flow table to see if those sales turned into cash.
What were third-quarter BIT Solution fluid and applicator sales?
Tomi highlighted strong applicator and disinfectant fluid sales in the first half, but did not report quarterly dollar figures for either product line in this preliminary release.
How many shares were issued for the $2.5 million debt swap?
Converting $2.5 million of notes wiped out most of Tomi's debt and lifted equity to $3 million–$4 million, but the release did not state the ending share count.